Trial Profile
Open-label Phase 3b Study to Investigate the Safety of Ross River Virus (RRV) Vaccine From 6 to 12 Months After the Third Vaccination in Healthy Adults (Follow up to Precursor Study 880801) [EXTENSION OF 700191470]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2018
Price :
$35
*
At a glance
- Drugs Ross River virus vaccine (Primary) ; Aluminium hydroxide
- Indications Ross River virus infections
- Focus Adverse reactions; Registrational
- Sponsors Baxter Healthcare Corporation
- 05 Apr 2013 New trial record
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.